Piramal Pharma Limited
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is headquartered in India and operates extensively across key regions, including North America, Europe, and Asia. Founded in 1988, the company has achieved significant milestones, establishing itself as a leader in both contract development and manufacturing, as well as in the formulation of complex generics. Piramal Pharma's core offerings include a diverse range of pharmaceutical products and services, with a strong emphasis on innovative drug delivery systems and advanced therapies. Their commitment to quality and sustainability sets them apart in a competitive market. With a robust portfolio and a focus on research and development, Piramal Pharma Limited continues to enhance its market position, contributing to healthcare solutions worldwide.
DitchCarbon Score
How does Piramal Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Limited's score of 34 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Piramal Pharma Limited's reported carbon emissions
In 2023, Piramal Pharma Limited reported total greenhouse gas emissions of approximately 505,868,000 kg CO2e, comprising 55,229,000 kg CO2e from Scope 1, 75,494,000 kg CO2e from Scope 2, and 450,639,000 kg CO2e from Scope 3 emissions. This marked a slight decrease in Scope 1 emissions compared to 2022, where they were about 56,578,000 kg CO2e, while Scope 2 emissions also saw a reduction from 85,844,000 kg CO2e in the previous year. Piramal Pharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. Additionally, the company targets a 25% reduction in Scope 3 emissions, which include significant categories such as purchased goods and services, fuel and energy-related activities, and upstream transportation and distribution. These commitments align with industry standards and reflect Piramal Pharma's dedication to addressing climate change within the pharmaceutical sector. The company has not yet committed to a net-zero target but is actively working towards substantial emissions reductions in the near term.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 41,396,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,243,220 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Piramal Pharma Limited is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
